Cite
HARVARD Citation
Armagan, B. et al. (n.d.). SAT0172 ANTIBODIES TO BOTH RO52 AND RO60 DEFINE A SUBSET OF SJÖGREN'S MOST SUITABLE FOR CLINICAL TRIALS OF AGENTS TARGETING LYMPHOPROLIFERATIONS. Annals of the rheumatic diseases. p. 1160. [Online].